Pain Treatment Method Using NR4A1 Agonists, 7 Compounds Listed
Summary
The USPTO granted patent US12611393B2 to inventors Temugin Berta and Raquel Tonello on April 28, 2026. The patent covers a method of treating post-operative pain or chemotherapy-induced neuropathic pain by administering a therapeutically effective amount of an NR4A1 agonist to a diagnosed patient. Seven specific agonist compounds are listed in the claims, including Cytosporone B, TMPA, CCE9, THPN, C-DIM-5, DIM-C-Ph, and DIM-C-pPhOCH3, with 12 claims total.
“The method treats a patient having post-operative pain or chemotherapy induced neuropathic pain, and it involves a) assessing the patient to determine if they are experiencing post-operative pain or chemotherapy induced neuropathic pain, and if such pain is diagnosed; b) administering to the patient a therapeutically effective amount of an agonist for the nuclear receptor subfamily 4, group A, member 1 (NR4A1).”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO granted patent US12611393B2 to inventors Temugin Berta and Raquel Tonello, covering a method of treating post-operative pain and chemotherapy-induced neuropathic pain through administration of NR4A1 (nuclear receptor subfamily 4, group A, member 1) agonists. The patent discloses seven specific agonist compounds: Cytosporone B, Ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)-phenyl] acetate (TMPA), CCE9, THPN, C-DIM-5, DIM-C-Ph, and DIM-C-pPhOCH3. The method comprises assessing a patient for post-operative or chemotherapy-induced neuropathic pain and, upon diagnosis, administering a therapeutically effective amount of one of the listed agonists.
Pharmaceutical and biotechnology companies developing pain-management therapeutics should review the compound list for any overlap with active research programs. The patent's broad claim to NR4A1 agonism for neuropathic pain indications may affect freedom-to-operate considerations for competing therapies in this mechanism class. Drug manufacturers with related compounds in development should conduct IP clearance analyses to assess potential overlap with the granted claims.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treatment of pain by targeting NR4A1
Grant US12611393B2 Kind: B2 Apr 28, 2026
Inventors
Temugin Berta, Raquel Tonello
Abstract
The present invention involves a method of treating pain. The method treats a patient having post-operative pain or chemotherapy induced neuropathic pain, and it involves a) assessing the patient to determine if they are experiencing post-operative pain or chemotherapy induced neuropathic pain, and if such pain is diagnosed; b) administering to the patient a therapeutically effective amount of an agonist for the nuclear receptor subfamily 4, group A, member 1 (NR4A1). In one embodiment, the agonist is selected from the group consisting of Cytosporone B, Ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)-phenyl] acetate (TMPA), 1,3,7-trihydroxy-2,4-diprenylxanthone (CCE9), 1-(3,4,5-trihydroxyphenyl)-nonan-1-one (THPN), DIM-C-pPhOCH3 (C-DIM-5), 1,1-bis(3′-indolyl)-1-(phenyl)methane (DIM-C-Ph) and 1,1-bis(3′-indolyl)-1-(p-anisyl)methane (DIM-C-pPhOCH3).
CPC Classifications
A61K 2300/00 A61K 31/121 A61K 31/216 A61K 31/337 A61K 31/353 A61K 31/404 A61K 45/06 A61P 25/02 A61P 25/04
Filing Date
2020-08-31
Application No.
17909513
Claims
12
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.